Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch + Lomb Corporation (BLCO)
NYSE:BLCO
RESEARCH TOOLSreports
Bausch + Lomb Corporation (BLCO) Stock Price & Analysis
75 Followers
BLCO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.16 - $21.23
Previous Close$14.72
Volume303.26K
Average Volume (3M)463.58K
Market Cap
$5.17B
Enterprise Value$9.51B
Total Cash (Recent Filing)$315.00M
Total Debt (Recent Filing)$4.58B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 01, 2024EPS Estimate
$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding351,482,100
10 Day Avg. Volume271,444
30 Day Avg. Volume463,579
Standard Deviation0.09
R-Squared0.09
Alpha-0.00630
Financial Highlights & Ratios
Price to Book (P/B)-3.74
Price to Sales (P/S)5.64
Price to Cash Flow (P/CF)32.00
P/FCF Ratio8.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.34
Enterprise Value/Gross Profit3.79
Enterprise Value/Ebitda14.45
Forecast
1Y Price Target
$19.06Price Target Upside29.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Bausch + Lomb Corporation News
PremiumCompany Announcements
Bausch + Lomb Showcases Innovations at EuDEC 2024
PremiumCompany Announcements
Bausch + Lomb Unveils New Daily Astigmatism Lenses
PremiumCompany Announcements
Bausch + Lomb Debuts Nutritional Dry Eye Relief
PremiumCompany Announcements
Bausch + Lomb Shareholders Back Expansion and Leadership
PremiumCompany Announcements
Bausch + Lomb Showcases Eye Care InnovationsBulls Say, Bears Say
Bulls Say
Dry Eye Market ShareMiebo and Xiidra together hold more than 30% of the dry eye treatment market.
Product LaunchBLCO fully realigned and integrated its DED reps with an ongoing DTC campaign to support the Miebo launch and re-energize Xiidra.
Sales PerformanceIQVIA data implies annualized Miebo sales well ahead of BLCO's guide.
Bears Say
Financial GuidanceDespite certain metrics tracking well ahead, BLCO only reiterated most of FY24 guidance.
Market UncertaintySpin uncertainty remains a key overhang on the stock.
Sales PerformanceQ1 Xiidra sales fell 12% year-over-year due to high deductibles, restricted patient access, and sales force realignment.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was $13.16 and its highest was $21.23 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Currently, no data Available
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Aug 01, 2024 which is in 24 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on May 01, 2024. The company reported $0.07 earnings per share for the quarter, the consensus estimate of $0.07 by $0.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is $0.13.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 350,992,250 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of $0.07 in its last earnings report, expectations of $0.07. Following the earnings report the stock price went down -5.502%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Among the largest hedge funds holding Bausch + Lomb Corporation’s share is Goldentree Asset Management Lp. It holds Bausch + Lomb Corporation’s shares valued at 82M.
---
Bausch + Lomb Corporation Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.06 (29.48% Upside)
$19.06 (29.48% Upside)
Blogger Sentiment
Bullish
BLCO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 65.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.58%
12-Months-Change
Fundamentals
Return on Equity
-4.94%
Trailing 12-Months
Asset Growth
19.02%
Trailing 12-Months
Company Description
Bausch + Lomb Corporation
Bausch & Lomb Corp is a global eye health company dedicated towards protecting and enhancing the gift of sight for millions of people around the world. It holds portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
---
BLCO Company Deck
---
BLCO Earnings Call
Q1 2024
0:00 / 0:00
---
BLCO Stock 12 Month Forecast
Average Price Target
$19.06
▲(29.48% Upside)
Technical Analysis
Best Analysts Covering BLCO
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
-0.14%
assigned a buy rating 2 months ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -0.14% per trade.
---